Supplementary Tables – Generalizability of ORIENT-11 Trial Results to a US Standard of Care Cohort with Advanced Non-Small Cell Lung Cancer

<b>Supplementary Table 1. Baseline Assessment between target US population and ORIENT-11 SPP and PPP arms before and after Adjustment^a</b> <b>Abbreviations: </b>BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; EB, entropy balancing; IPW, inverse probability weighting; N, number of patients in population; n, number of patients in the specified category; PPP, placebo+pemetrexed+platinum; PD-L1, programmed death-ligand 1; SD, standard deviation; SPP, sintilimab+pemetrexed+platinum; SMD, standardized mean difference between SPP and <b>Target US Population or between PPP and Target US Population</b> * Data from Yang et al. 2020 ^aAdjustment refers to IPW (primary analysis) and EB (sensitivity analysis) ^bAge was recorded at first line start date ^cDuration of disease was reported from advanced diagnosis to first line start date

补充表1. 校正^a前后美国目标人群与ORIENT-11试验的SPP组及PPP组的基线特征评估
缩写：BMI（body mass index，体重指数）；ECOG PS（Eastern Cooperative Oncology Group performance status，东部肿瘤协作组体能状态评分）；EB（entropy balancing，熵平衡）；IPW（inverse probability weighting，逆概率加权）；N：人群总患者数；n：特定分类下的患者数；PPP（placebo+pemetrexed+platinum，安慰剂+培美曲塞+铂类方案）；PD-L1（programmed death-ligand 1，程序性死亡配体1）；SD（standard deviation，标准差）；SPP（sintilimab+pemetrexed+platinum，信迪利单抗+培美曲塞+铂类方案）；SMD：SPP组与美国目标人群，或PPP组与美国目标人群间的标准化均差。
* 数据来源：Yang等人，2020年
^a 校正方法包括逆概率加权（主要分析）与熵平衡（敏感性分析）
^b 年龄以一线治疗开始日期时的记录为准
^c 疾病时长指从晚期诊断至一线治疗开始的时间间隔